HealthCare Global Enterprises Ltd. reports Q4 & FY25 results
Revenue for Q4FY25 of INR 5,5851 Million, a growth of 18% (y-o-y); FY25 revenue stood at INR 22,228 Million, a growth of 16% (y-o-y) EBITDA for Q4FY25 of INR 1,070 Million, a growth of 14% (y-o-y)
Revenue for Q4FY25 of INR 5,5851 Million, a growth of 18% (y-o-y); FY25 revenue stood at INR 22,228 Million, a growth of 16% (y-o-y)
EBITDA for Q4FY25 of INR 1,070 Million, a growth of 14% (y-o-y) with 18.3% Margins
and PAT for Q4FY25 of INR 74 Million
HealthCare Global Enterprises Limited (“HCG”), the leader in India in specialty healthcare services focused on oncology and fertility announced its unaudited financial results for the quarter (“Q4”) and full year ended March 31st 2025.
Highlights for quarter ended March 31st, 2025
- Consolidated Income from Operations (“Revenue”) was INR 5,851 mn as compared to INR 4,946 mn in the corresponding quarter of the previous year, reflecting a year-on-year growth of 18%
- Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Adjusted EBITDA”) was INR 1,070 mn, as compared to INR 941 mn in the corresponding quarter of the previous year, a growth of 14% year-on-year
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Reported EBITDA”), was INR 1,057 mn, as compared to INR 920 mn in the corresponding quarter of the previous year, a growth of 15% year-on-year
- EBITDA for Established centers was INR 1,154 mn, a growth of 15% year-on-year
- EBITDA from Emerging centers was INR 70 mn, as compared to INR 49 mn in the corresponding quarter of the previous year
- Consolidated Profit after Taxes and Minority Interest (“PAT”) of INR 74 mn, as compared to INR 213 mn in the corresponding quarter of the previous year.
INR million except earnings per share
| Period ended Mar’25 | Q4-FY25 | Q4-FY24 | Growth (y-o-y) | |||||
| Income from Operations | 5,851 | 4,946 | 18% | |||||
| Adjusted EBITDA(1) | 1070 | 941 | 14% | |||||
| Margin (%) | 18.3% | 19.0% | ||||||
| Reported EBITDA | 1,057 | 920 | 15% | |||||
| Margin (%) | 18.1% | 18.6% | ||||||
| PBT | 136 | 282 | -52% | |||||
| PBT margin % | 2.3% | 5.7% | ||||||
| PAT (2) | 74 | 213 | -65% | |||||
| PAT margin % | 1.3% | 4.3% | ||||||
| Earnings per share (EPS) | 0.51 | 1.51 | – | |||||
- Adjusted EBITDA excluding ESOP; ESOP for one time cost for Q4FY25 is Rs 13.1 mn, for Q4FY24 is Rs 21.0 mn
- PAT after Minority Interest
Business Updates for Q4FY25
- Overall ARPOB stood at Rs. 44,236 vs. Rs. 42,741 in Q4FY24, a growth of 3.5%
- Overall AOR stood at 67.0% vs. 63.2% in Q4FY24
- Added 2 LINACs at Vizag and Nagpur and 1 PET CT in Africa
- RoCE (FY25 Annualized)
- RoCE for Established centers stood at 17.1% vs. 16.9% in FY24. RoCE pre-corporate allocations stands at 24.4%
- RoCE for Emerging centers stood at -18.1% vs. -26.4% in FY24. RoCE pre-corporate allocations stands at -13.2%
- Several regions delivered high double-digit revenue growth on YoY basis
- Markets like Borivali and South Mumbai grew by 38% and 37% YoY respectively
- Nagpur & Jaipur grew by 28% & Kolkata grew by 22% YoY
